At a glance
- Semax is a seven-amino-acid analogue based on the ACTH(4–7) region with a Pro-Gly-Pro extension. It is studied in neurotrophic, neuronal-stress, gene-expression, and cognition-related models without the classic adrenal activity of full ACTH.
- Semax has regional medical-use history, particularly in Russia, but is not FDA- or Health Canada-approved. Much of the human literature is small, regional, or not independently replicated to modern registration-trial standards.
- Use defined neurotrophin, gene-expression, oxidative-stress, or neuronal-survival endpoints instead of a general cognition label.
- Distinguish the Semax sequence from ACTH and from shorter ACTH fragments when choosing controls.
What SEMAX is—and what the name does not establish
Semax is a seven-amino-acid analogue based on the ACTH(4–7) region with a Pro-Gly-Pro extension. It is studied in neurotrophic, neuronal-stress, gene-expression, and cognition-related models without the classic adrenal activity of full ACTH.
Rather than one settled receptor target, research reports changes in neurotrophin expression, melanocortin-related signalling, oxidative stress, and peptide-regulatory systems. In plain language, Semax is a multi-signal neuroresearch peptide, and the exact pathway remains model-dependent.
Questions to settle before interpreting a result
A useful SEMAX study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Use defined neurotrophin, gene-expression, oxidative-stress, or neuronal-survival endpoints instead of a general cognition label.
- Distinguish the Semax sequence from ACTH and from shorter ACTH fragments when choosing controls.
- Keep preclinical neuroprotection results separate from human functional outcomes and route-specific clinical reports.
How to read the SEMAX evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Preclinical evidence
- Design
- Neurotrophin and neuronal-response signals have been reported
- Finding
- Cell and animal studies have described changes in BDNF-related expression, oxidative stress, and injury responses. These findings support further mechanism work, not a guaranteed cognitive or recovery effect.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Human evidence
- Design
- The clinical literature needs cautious reading
- Finding
- Regional studies are part of the evidence base, but differences in trial reporting, route, comparators, and independent replication limit how confidently broad claims can be made.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Best framing
- Design
- A defined analogue—not “ACTH without side effects”
- Finding
- Semax was derived from an ACTH fragment, but its biology should be described from direct Semax evidence rather than assumed from the parent hormone.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
Semax has regional medical-use history, particularly in Russia, but is not FDA- or Health Canada-approved. Much of the human literature is small, regional, or not independently replicated to modern registration-trial standards.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampusBrain Research · 2006
Primary rodent study of a defined molecular endpoint; it is not evidence of a clinical cognitive outcome.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Explore SEMAX
Review available strengths, pricing, stock status, and product documentation.